More on CSLLY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.41 |
|
|||
| Open | $25.13 | ||||
| 52 Wk High | $45.60 | ||||
| 52 Wk Low | $33.39 | ||||
| Day High | $25.50 | ||||
| Day Low | $25.05 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 304,463 | ||||
- Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited
- Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- CSL Ltd. (CSL:AU) (CSLLY) PT Lowered to AUD225 at CLSA
- CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
- Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenz
- KDIGO guidelines include FILSPARI for IgA nephropathy treatment
- CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
- CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
- VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
- U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patie
Entities mentioned with CSLLY
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- AdCom | View Related Stories »
- Vanguard | View Related Stories »
- JPMorgan | View Related Stories »
- Earnings | View Related Stories »
- Goldman Sachs | View Related Stories »
- Show More...
